- Published on
Ophthalmology – Benign Conjunctival Lesions
Benign conjunctival lesions represent a diverse group of nonmalignant growths affecting the conjunctiva, including papilloma, Kaposi’s sarcoma, limbal dermoid, sarcoidosis-related nodules, and pyogenic granuloma. These lesions have a low potential for malignant transformation but vary widely in their causes, clinical appearance, and management. While many are asymptomatic, they may produce symptoms due to mass effect or cosmetic concerns.
The epidemiology varies depending on the specific lesion. Kaposi’s sarcoma may involve the ocular adnexa in a subset of patients with systemic disease, particularly in immunocompromised individuals. Sarcoidosis can involve the conjunctiva in a smaller proportion of systemic cases. Limbal dermoids are typically congenital and present early in life, whereas other lesions such as papillomas or pyogenic granulomas may occur at any age depending on underlying risk factors.
Risk factors differ among lesion types. Conjunctival papillomas are associated with human papillomavirus (HPV), often transmitted during childbirth or through direct contact, and may also be influenced by ultraviolet exposure. Kaposi’s sarcoma is strongly linked to immunosuppression, including HIV/AIDS, chemotherapy, organ transplantation, and advanced age. Limbal dermoids are congenital lesions, sometimes associated with syndromes such as Goldenhar syndrome. Sarcoidosis is more common in African American patients and is associated with systemic granulomatous disease. Pyogenic granulomas often arise following ocular surgery, trauma, or chronic inflammation as part of an exaggerated wound-healing response.
The pathophysiology reflects the underlying cause of each lesion. Papillomas result from viral-induced epithelial proliferation, while Kaposi’s sarcoma arises from vascular proliferation driven by human herpesvirus-8. Limbal dermoids are choristomas containing normal tissue in an abnormal location, often including hair follicles and sebaceous glands. Sarcoidosis leads to noncaseating granulomatous inflammation, and pyogenic granulomas represent reactive fibrovascular proliferation following injury or inflammation.
Patients may present with a variety of symptoms, although many lesions are discovered incidentally. When symptomatic, patients may report foreign body sensation, irritation, tearing, itching, photophobia, or blurred vision. Larger lesions can cause mechanical effects such as ptosis, trichiasis, or poor eyelid apposition. A thorough history is important, including immune status, systemic symptoms suggestive of sarcoidosis, prior ocular surgery or trauma, and congenital onset in the case of limbal dermoids.
On examination, the appearance of the lesion often suggests the diagnosis. Papillomas typically appear as pink-red, fleshy, pedunculated or sessile lesions, sometimes with a verrucous surface. Kaposi’s sarcoma presents as a reddish-purple, flat or nodular lesion. Sarcoid lesions are usually yellow or salmon-colored nodules, often located in the inferior conjunctival fornix. Limbal dermoids appear as yellowish-white, well-circumscribed masses near the limbus and may contain fine hairs. Pyogenic granulomas are highly vascular, red, elevated lesions often attached by a stalk. Secondary findings may include conjunctival swelling, corneal irritation, or surface damage.
Diagnosis is primarily clinical but may be supported by laboratory and imaging studies when systemic disease is suspected. For example, HIV testing is indicated in suspected Kaposi’s sarcoma, while serum angiotensin-converting enzyme levels and chest imaging may aid in diagnosing sarcoidosis. Biopsy, either incisional or excisional, is recommended when there is concern for malignancy or when the diagnosis is uncertain.
Management depends on the specific lesion and symptom severity. Many lesions, such as papillomas and pyogenic granulomas, may resolve spontaneously and can be observed initially. Topical treatments, such as steroids for sarcoidosis or lubrication for limbal dermoids, may provide symptomatic relief. Kaposi’s sarcoma is managed primarily with systemic therapy such as highly active antiretroviral therapy in HIV-positive patients. For persistent, symptomatic, or suspicious lesions, surgical excision is often indicated, sometimes combined with adjunctive therapies such as cryotherapy or topical medications.
The prognosis for benign conjunctival lesions is generally excellent. Most lesions remain stable or resolve with appropriate management, although recurrence can occur, particularly after surgical removal. Complications are uncommon but may include scarring, infection, or, in the case of limbal dermoids, residual corneal opacity or refractive error. In some cases, systemic complications may arise depending on the underlying associated condition, emphasizing the importance of a comprehensive evaluation.
- Published on
Ophthalmology – Best’s Vitelliform Macular Dystrophy
Best’s vitelliform macular dystrophy, also known as Best’s disease, is a rare inherited retinal disorder characterized by bilateral involvement of the macula and a distinctive yellow “egg-yolk” lesion. It follows an autosomal dominant inheritance pattern and is caused by mutations in the BEST1 gene on chromosome 11q13, which encodes the bestrophin-1 protein. Although the age of onset is variable, the disease most commonly presents during childhood or adolescence.
The underlying pathophysiology involves dysfunction of bestrophin-1, a calcium-activated chloride channel located in the retinal pigment epithelium (RPE). This dysfunction leads to impaired ion transport and accumulation of lipofuscin between the neurosensory retina and the RPE. Over time, this buildup produces the characteristic vitelliform lesion and contributes to progressive retinal changes.
Patients often present with mild visual symptoms such as blurred vision or metamorphopsia, although some may remain asymptomatic in early stages. A positive family history of retinal dystrophy is an important clue. On examination, the anterior segment is typically normal, while fundus evaluation reveals the classic yellow lesion in the central macula. The disease progresses through several stages, beginning with subtle RPE changes and advancing to the vitelliform “egg-yolk” stage. Later stages may show fragmentation of the lesion (“scrambled egg”), layering of material (pseudohypopyon), and eventual atrophy or scarring. In some cases, complications such as choroidal neovascularization can develop.
Diagnostic testing plays a key role in confirming the diagnosis. A hallmark finding is a normal full-field electroretinogram (ERG) with an abnormal electrooculogram (EOG), reflecting RPE dysfunction. The Arden ratio is typically reduced. Imaging studies such as optical coherence tomography (OCT) demonstrate subretinal deposits and structural changes, while fundus autofluorescence shows increased autofluorescence corresponding to lipofuscin accumulation. Fluorescein angiography may reveal blockage from lesions or leakage if neovascularization is present. Genetic testing can confirm mutations in the BEST1 gene.
There is no specific medical treatment for Best’s disease itself. Management primarily involves observation and regular follow-up with a retina specialist. Patients are monitored for disease progression and complications, particularly choroidal neovascularization. If such complications arise, treatment options include intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy or photodynamic therapy.
The prognosis is generally favorable, with many patients maintaining visual acuity of 20/40 or better for a significant portion of their lives. However, visual outcomes can vary depending on disease progression and the development of complications. Choroidal neovascularization remains the most important cause of vision loss in affected individuals. Genetic counseling is recommended for patients and their families due to the hereditary nature of the condition.
- Published on
Ophthalmology – Birth Trauma to the Eye
Birth trauma to the eye refers to ocular, adnexal, or facial injuries sustained during childbirth due to mechanical forces. These injuries may directly involve the eye or occur secondarily as part of broader cranial, neurologic, or facial trauma. Although relatively uncommon, birth-related injuries can have important visual consequences if not identified and managed early.
The incidence of birth trauma (both ophthalmic and non-ophthalmic) is estimated at 6–8 cases per 1,000 live births. Several risk factors increase the likelihood of such injuries, including large birth weight (especially greater than 4500 g), instrument-assisted deliveries such as forceps or vacuum extraction, prolonged or difficult labor, breech presentation, cephalopelvic disproportion, and reduced amniotic fluid (oligohydramnios). While cesarean section may be considered in high-risk cases, it does not completely eliminate the risk of injury.
The underlying pathophysiology often involves visual deprivation during a critical period of development, which can lead to amblyopia. This may result from structural abnormalities such as corneal distortion, irregular astigmatism, or eyelid ptosis that obstructs the visual axis. Injuries may be primary, directly affecting ocular tissues, or secondary, resulting from associated neurologic or vascular damage.
Clinical findings vary depending on the type and severity of injury. A classic finding is vertical or oblique breaks in Descemet’s membrane of the cornea, typically associated with forceps delivery. Other signs include an asymmetric red reflex, eyelid bruising or lacerations, conjunctival swelling (chemosis), and subconjunctival hemorrhage. Retinal hemorrhages may occur, particularly in association with intracranial trauma. Cranial nerve injuries can also be present, such as facial nerve palsy, which leads to incomplete eyelid closure, or third nerve involvement causing ptosis. Ptosis itself may arise from mechanical swelling, nerve injury, or disruption of the levator muscle.
Diagnosis is primarily clinical, based on careful ocular and neurologic examination. Neuroimaging may be required if there are associated neurologic signs. Histologically, corneal injuries reveal characteristic breaks in Descemet’s membrane. Early consultation with a pediatric ophthalmologist is essential to assess the extent of injury and prevent long-term complications.
Management depends on the specific injury. Corneal tears involving Descemet’s membrane may lead to corneal edema (hydrops) but often resolve spontaneously over weeks with observation, though monitoring for scarring is important. Superficial injuries such as abrasions or lacerations require cleaning, antibiotic ointment, and sometimes suturing. Canalicular injuries require specialized surgical repair. Facial nerve palsy is managed by protecting the cornea from exposure using frequent lubrication and, if necessary, patching. Ptosis treatment is directed at the underlying cause, with surgical correction considered when there is a risk of amblyopia.
Prognosis is generally excellent if amblyogenic factors are identified and treated early. However, complications can occur, including amblyopia due to visual deprivation, persistent ptosis, and exposure keratopathy. Early detection, close monitoring, and timely intervention are critical to preserving normal visual development.
- Published on
Ophthalmology – Blebitis
Blebitis is an infection involving a filtering bleb, which is a subconjunctival reservoir intentionally created during glaucoma surgery (such as trabeculectomy) to allow aqueous humor drainage. It is important to distinguish blebitis from bleb-associated endophthalmitis (BAE), a more severe condition in which infection extends into the vitreous. Blebitis is limited to the anterior segment, whereas BAE involves deeper intraocular structures and carries a much worse prognosis.
This condition most commonly occurs following trabeculectomy, especially when antifibrotic agents like mitomycin C are used. The incidence varies, with blebitis occurring in approximately 5.7% of such cases, while BAE is less common but more serious. Risk factors include inferiorly located blebs, thin or avascular blebs, bleb leaks, prior infections such as conjunctivitis or blepharitis, repeated surgical manipulation, and chronic antibiotic use. These factors compromise the natural protective barrier of the conjunctiva, allowing microorganisms to penetrate.
The pathophysiology differs depending on timing. Early-onset infections (within one month of surgery) are typically due to contamination during surgery, often involving less virulent organisms. Late-onset infections occur months to years later and are usually caused by more aggressive organisms that can penetrate compromised bleb tissue or enter through leaks. Common causative organisms include Staphylococcus epidermidis and Staphylococcus aureus for blebitis and early infections, while Streptococcus species, Haemophilus influenzae, and gram-negative bacteria are more common in late-onset BAE.
Patients with blebitis usually present with a red eye, mild discomfort, and possibly decreased vision. In contrast, BAE often presents abruptly with severe pain, photophobia, discharge, and rapid visual loss. On examination, blebitis is characterized by localized conjunctival injection around the bleb, a milky or cloudy appearance of the bleb, and sometimes purulent material. Anterior chamber inflammation may be present. The key distinguishing feature of BAE is vitreous involvement, often accompanied by hypopyon, which should be considered endophthalmitis until proven otherwise.
Diagnosis is primarily clinical but may be supported by additional testing. Slit-lamp examination is essential, and B-scan ultrasonography may be required if the posterior segment view is obscured. Cultures from purulent material, anterior chamber taps, or vitreous samples may help identify the causative organism, although treatment is often initiated empirically due to the urgency of the condition.
Management requires prompt and aggressive treatment. Blebitis is typically treated with intensive topical fortified antibiotics such as vancomycin and tobramycin or cefazolin, administered frequently. Mild cases may be treated with high-frequency topical fluoroquinolones. In contrast, BAE is a medical emergency requiring intravitreal antibiotics, typically vancomycin combined with ceftazidime (or amikacin if needed). Repeat intravitreal injections may be necessary, and vitrectomy is often considered. Adjunctive oral antibiotics may be used, and corticosteroids may be cautiously introduced to control inflammation.
Close follow-up is critical, often requiring daily or even multiple daily evaluations, as progression from blebitis to BAE can occur rapidly. Patients must be educated to seek immediate care for symptoms such as redness, pain, or blurred vision.
The prognosis of blebitis is generally good with early treatment, especially when caused by less virulent organisms. However, bleb-associated endophthalmitis carries a poor prognosis despite aggressive therapy, with many patients experiencing significant vision loss. Complications include bleb failure, intraocular scarring, glaucoma progression, cataract formation, retinal detachment, and, in severe cases, loss of the eye.
- Published on
Ophthalmology – Blepharitis
Blepharitis is a chronic, recurrent inflammation of the eyelid margin and is one of the most common conditions encountered in ophthalmology practice. It is broadly divided into two types: anterior blepharitis (also called seborrheic blepharitis), which affects the front of the eyelid at the base of the eyelashes, and posterior blepharitis (meibomian gland dysfunction), which involves the meibomian glands located behind the eyelashes. The condition is common, affecting up to nearly half of patients seen in eye clinics, and although more frequently noted in individuals of Northern European descent, it occurs across all populations.
The underlying mechanisms differ between the two types. In anterior blepharitis, excessive scaling of the skin at the eyelid margin, often associated with seborrheic dermatitis and colonization by organisms such as Malassezia, leads to inflammation. In posterior blepharitis, abnormal composition and secretion of lipids from the meibomian glands result in gland obstruction and inflammation. Both conditions are often influenced by genetic predisposition and may run in families.
Patients typically present with symptoms of eyelid irritation, including itching, burning, redness, and fluctuating discomfort throughout the day. Many also experience symptoms of evaporative dry eye, such as foreign body sensation and blurred vision. Those with anterior blepharitis often notice flaky debris at the base of the eyelashes, while patients with meibomian gland dysfunction may describe thick, waxy secretions along the eyelid margin or recurrent eyelid lumps such as chalazia.
On examination, anterior blepharitis is characterized by crusting and scaling at the lash line, redness of the anterior lid margin, and debris in the tear film, often accompanied by punctate keratitis. Posterior blepharitis shows plugged meibomian gland orifices with thick, yellowish secretions, diffuse lid margin redness, and abnormal tear film lipid layer. Associated findings may include telangiectatic vessels along the lid margin, chalazia, and signs of acne rosacea.
Diagnosis is clinical and based on history and slit-lamp examination. Laboratory testing is rarely required, although cultures may occasionally be performed in resistant cases. Histopathologic findings include epidermal changes and inflammatory infiltrates in anterior blepharitis, and gland obstruction with inflammatory changes in meibomian gland dysfunction.
Management focuses on long-term control rather than cure. For anterior blepharitis, the mainstay of treatment is eyelid hygiene, particularly regular eyelash scrubs using a dilute baby shampoo solution. If needed, topical antibiotic ointments may be added. For posterior blepharitis, warm compresses applied several times daily help liquefy gland secretions, followed by expression of the glands. In more persistent cases, topical azithromycin or oral doxycycline may be used, though these are avoided in young children and during pregnancy.
An important aspect of management is treating associated evaporative dry eye, which often contributes more to symptoms than the blepharitis itself. This may include artificial tears, punctal plugs, or topical anti-inflammatory therapy such as cyclosporine. Dietary supplementation with omega-3 fatty acids may also provide benefit in meibomian gland dysfunction.
Blepharitis is a lifelong condition with a tendency for recurrence, but the prognosis is excellent with appropriate management, and significant vision loss is not expected. Complications can include chronic dry eye, marginal keratitis, and chalazia. Patient education regarding the chronic nature of the disease and the importance of consistent eyelid hygiene is essential for successful long-term control.
- Published on
Ophthalmology – Birdshot Chorioretinopathy
Birdshot chorioretinopathy is a rare, chronic, bilateral form of posterior uveitis characterized by distinctive cream-colored lesions at the level of the choroid. These lesions radiate outward from the optic nerve, resembling the scattered pattern of birdshot from a shotgun. The disease is strongly associated with the HLA-A29 allele, with over 90% of affected individuals testing positive, making it one of the strongest HLA-disease associations in medicine.
This condition primarily affects middle-aged adults, with an average onset around 50 years of age, and is more commonly seen in individuals of Caucasian descent. Both males and females are affected equally. Although the exact cause remains unclear, the disease is believed to be autoimmune in nature, likely involving a type IV hypersensitivity reaction targeting retinal or choroidal antigens.
Patients typically present with gradual, painless, bilateral visual decline. Common symptoms include floaters, nyctalopia (night vision difficulty), photopsias, photophobia, peripheral visual field loss, and impaired color vision. Despite these symptoms, the eyes may appear relatively quiet externally, with minimal anterior segment inflammation. On examination, mild to moderate vitreous inflammation is often present. The hallmark finding is the presence of multiple cream-colored choroidal lesions with indistinct borders. Cystoid macular edema (CME) is a frequent complication and a major cause of decreased visual acuity. Retinal vasculitis and optic disc edema may also be observed.
Diagnosis is largely clinical but supported by ancillary testing. HLA-A29 testing is highly sensitive and specific. Imaging studies are essential: fluorescein angiography shows early hypofluorescence and late leakage, while indocyanine green angiography often reveals more lesions than are clinically visible. Optical coherence tomography is useful for detecting macular edema. Electroretinography frequently shows reduced photopic and scotopic responses, and visual field testing often demonstrates peripheral constriction. It is important to exclude other causes of posterior uveitis, such as infections (e.g., syphilis, tuberculosis, Lyme disease), sarcoidosis, or intraocular lymphoma.
Management typically involves long-term immunosuppression. Corticosteroids, either systemic or local, are effective for initial control of inflammation, but due to the chronic nature of the disease and the side effects of prolonged steroid use, steroid-sparing immunomodulatory agents are often introduced early. These include medications such as cyclosporine, methotrexate, mycophenolate mofetil, and azathioprine. In refractory cases, biologic agents such as anti–tumor necrosis factor (TNF) therapies or intravenous immunoglobulin may be considered. Local steroid injections may also be used for severe inflammation or macular edema.
The disease course is typically chronic and progressive, with periods of exacerbation and remission. Close, long-term follow-up is essential, including regular monitoring with imaging and functional tests. Prognosis is guarded over time, as visual function may decline even when visual acuity appears relatively preserved. Complications such as cystoid macular edema, epiretinal membrane formation, glaucoma (often secondary to steroid use), choroidal neovascularization, and, rarely, optic nerve atrophy can contribute to vision loss.
- Published on
Ophthalmology – Anisocoria in Children
Anisocoria in children refers to a difference in pupil size of 0.5 mm or more between the two eyes. It is relatively common, with physiologic anisocoria accounting for the majority of cases and occurring in approximately 15–30% of the population. In these benign cases, there is no associated ocular or neurologic abnormality. However, anisocoria in children can occasionally indicate underlying pathology, making careful evaluation essential.
The causes of anisocoria range from benign physiologic variation to serious neurologic or ocular disease. Physiologic anisocoria is idiopathic and not associated with any risk factors. Other causes include trauma (ocular or systemic), inflammation such as iritis, meningitis, pharmacologic exposure to mydriatic or miotic agents, and congenital or acquired neurologic conditions. One particularly important cause is Horner syndrome, which may be congenital due to birth trauma or acquired due to neoplasms such as neuroblastoma. Third cranial nerve palsy, whether congenital or acquired, is another critical cause and may result from trauma, infection, tumors, or, rarely in children, aneurysms. Less common causes include Adie’s tonic pupil, pharmacologic dilation, traumatic iris damage, posterior synechiae, and anterior segment dysgenesis.
Pathophysiologically, anisocoria results from dysfunction or imbalance in the pupillary sphincter or dilator muscles, mechanical restriction of the iris, or disruption of the autonomic innervation to the pupil. In some cases, such as physiologic anisocoria, no structural or functional abnormality is identified.
A detailed history is essential in evaluation. Important aspects include the age of onset, duration, history of trauma (including birth trauma), prior surgeries, and associated symptoms such as ptosis, anhidrosis, or facial flushing. Reviewing old photographs can help determine whether the anisocoria is congenital or acquired. Symptoms such as ptosis or abnormal sweating may suggest Horner syndrome, while diplopia or abnormal eye movements may indicate third nerve palsy.
On physical examination, visual acuity is typically normal in physiologic anisocoria but may be reduced in conditions like third nerve palsy or Adie’s pupil due to amblyopia or accommodative dysfunction. Careful pupil examination is crucial. If anisocoria is greater in darkness, the smaller pupil is abnormal, suggesting conditions such as Horner syndrome or physiologic anisocoria. If anisocoria is greater in light, the larger pupil is abnormal, indicating possibilities such as third nerve palsy, Adie’s pupil, traumatic mydriasis, or pharmacologic dilation. Additional findings such as dilation lag, light-near dissociation, segmental iris constriction, iris heterochromia, and eyelid abnormalities can further aid diagnosis. Extraocular motility should also be assessed, as abnormalities may indicate third nerve involvement. A systemic examination, including palpation for masses in the abdomen or neck, is important when a neoplastic cause is suspected.
Diagnostic testing depends on the suspected underlying cause. In suspected Horner syndrome without clear birth trauma, urine testing for vanillylmandelic acid (VMA) and homovanillic acid (HVA) may be performed to screen for neuroblastoma, although imaging is often more sensitive. MRI of the brain, neck, chest, and abdomen is typically recommended when Horner syndrome is suspected. If third nerve palsy is suspected, MRI with magnetic resonance angiography may be indicated. Pharmacologic testing can also aid diagnosis: apraclonidine or cocaine drops for Horner syndrome, hydroxyamphetamine to localize the lesion, and dilute pilocarpine for Adie’s tonic pupil.
Management focuses on identifying and treating the underlying cause rather than the anisocoria itself. Physiologic anisocoria requires no treatment. In Adie’s tonic pupil, dilute pilocarpine may be used to improve symptoms and cosmesis. Posterior synechiae due to iritis may be treated with mydriatic agents and anti-inflammatory therapy. Amblyopia, which may occur in conditions like third nerve palsy or Adie’s pupil, should be managed with refractive correction, patching, or atropine penalization. Cosmetic contact lenses may be considered in older children if appearance is a concern. Urgent referral is required if a neoplasm is suspected, and infants with Adie’s pupil should be evaluated by pediatric neurology to exclude systemic disorders.
Follow-up depends on the underlying cause. Physiologic anisocoria does not require ongoing monitoring. Children with third nerve palsy or Adie’s pupil should be followed to monitor for amblyopia. Suspected but unconfirmed Horner syndrome may require reassessment and repeat testing after several months. Conditions such as anterior segment dysgenesis require monitoring for complications like glaucoma.
The prognosis is excellent for physiologic anisocoria, with no impact on vision or development. For other causes, the outcome depends on the underlying condition. Early identification is critical, particularly in cases associated with serious conditions such as neuroblastoma, where prompt diagnosis can be life-saving.
Anisocoria in children refers to a difference in pupil size of 0.5 mm or more between the two eyes. It is relatively common, with physiologic anisocoria accounting for the majority of cases and occurring in approximately 15–30% of the population. In these benign cases, there is no associated ocular or neurologic abnormality. However, anisocoria in children can occasionally indicate underlying pathology, making careful evaluation essential.
The causes of anisocoria range from benign physiologic variation to serious neurologic or ocular disease. Physiologic anisocoria is idiopathic and not associated with any risk factors. Other causes include trauma (ocular or systemic), inflammation such as iritis, meningitis, pharmacologic exposure to mydriatic or miotic agents, and congenital or acquired neurologic conditions. One particularly important cause is Horner syndrome, which may be congenital due to birth trauma or acquired due to neoplasms such as neuroblastoma. Third cranial nerve palsy, whether congenital or acquired, is another critical cause and may result from trauma, infection, tumors, or, rarely in children, aneurysms. Less common causes include Adie’s tonic pupil, pharmacologic dilation, traumatic iris damage, posterior synechiae, and anterior segment dysgenesis.
Pathophysiologically, anisocoria results from dysfunction or imbalance in the pupillary sphincter or dilator muscles, mechanical restriction of the iris, or disruption of the autonomic innervation to the pupil. In some cases, such as physiologic anisocoria, no structural or functional abnormality is identified.
A detailed history is essential in evaluation. Important aspects include the age of onset, duration, history of trauma (including birth trauma), prior surgeries, and associated symptoms such as ptosis, anhidrosis, or facial flushing. Reviewing old photographs can help determine whether the anisocoria is congenital or acquired. Symptoms such as ptosis or abnormal sweating may suggest Horner syndrome, while diplopia or abnormal eye movements may indicate third nerve palsy.
On physical examination, visual acuity is typically normal in physiologic anisocoria but may be reduced in conditions like third nerve palsy or Adie’s pupil due to amblyopia or accommodative dysfunction. Careful pupil examination is crucial. If anisocoria is greater in darkness, the smaller pupil is abnormal, suggesting conditions such as Horner syndrome or physiologic anisocoria. If anisocoria is greater in light, the larger pupil is abnormal, indicating possibilities such as third nerve palsy, Adie’s pupil, traumatic mydriasis, or pharmacologic dilation. Additional findings such as dilation lag, light-near dissociation, segmental iris constriction, iris heterochromia, and eyelid abnormalities can further aid diagnosis. Extraocular motility should also be assessed, as abnormalities may indicate third nerve involvement. A systemic examination, including palpation for masses in the abdomen or neck, is important when a neoplastic cause is suspected.
Diagnostic testing depends on the suspected underlying cause. In suspected Horner syndrome without clear birth trauma, urine testing for vanillylmandelic acid (VMA) and homovanillic acid (HVA) may be performed to screen for neuroblastoma, although imaging is often more sensitive. MRI of the brain, neck, chest, and abdomen is typically recommended when Horner syndrome is suspected. If third nerve palsy is suspected, MRI with magnetic resonance angiography may be indicated. Pharmacologic testing can also aid diagnosis: apraclonidine or cocaine drops for Horner syndrome, hydroxyamphetamine to localize the lesion, and dilute pilocarpine for Adie’s tonic pupil.
Management focuses on identifying and treating the underlying cause rather than the anisocoria itself. Physiologic anisocoria requires no treatment. In Adie’s tonic pupil, dilute pilocarpine may be used to improve symptoms and cosmesis. Posterior synechiae due to iritis may be treated with mydriatic agents and anti-inflammatory therapy. Amblyopia, which may occur in conditions like third nerve palsy or Adie’s pupil, should be managed with refractive correction, patching, or atropine penalization. Cosmetic contact lenses may be considered in older children if appearance is a concern. Urgent referral is required if a neoplasm is suspected, and infants with Adie’s pupil should be evaluated by pediatric neurology to exclude systemic disorders.
Follow-up depends on the underlying cause. Physiologic anisocoria does not require ongoing monitoring. Children with third nerve palsy or Adie’s pupil should be followed to monitor for amblyopia. Suspected but unconfirmed Horner syndrome may require reassessment and repeat testing after several months. Conditions such as anterior segment dysgenesis require monitoring for complications like glaucoma.
The prognosis is excellent for physiologic anisocoria, with no impact on vision or development. For other causes, the outcome depends on the underlying condition. Early identification is critical, particularly in cases associated with serious conditions such as neuroblastoma, where prompt diagnosis can be life-saving.
- Published on
Ophthalmology – Acute Multifocal Placoid Pigment Epitheliopathy (AMPPE)
Acute multifocal placoid pigment epitheliopathy (AMPPE) is a rare, acquired inflammatory disorder affecting the retinal pigment epithelium (RPE) and choroid. It typically presents with multiple yellowish-white placoid lesions at the level of the RPE, most often involving the posterior pole and macula. The condition is frequently bilateral, and lesions are often seen in different stages of evolution, with healing characterized by areas of RPE hyperplasia. AMPPE is generally considered a self-limited condition, although it can occasionally be associated with systemic complications.
The exact incidence is unknown due to its rarity. Some genetic associations have been reported, particularly with HLA-B7 and HLA-DR2, suggesting a possible immunologic predisposition. The underlying pathophysiology is thought to involve choroidal vascular compromise, leading to secondary ischemia and inflammation of the RPE. Although the precise etiology remains unclear, approximately one-third of patients report a preceding viral-like illness, supporting the possibility of an immune-mediated or post-infectious mechanism.
Patients typically present with sudden, painless visual loss, which may affect one or both eyes. Visual symptoms can include blurred vision or scotomas. On funduscopic examination, characteristic findings include multiple, flat, yellowish-white lesions at the level of the RPE and choroid, often located in the macular region. These lesions may appear in various stages, with some resolving while others are newly forming. As lesions heal, they leave behind areas of pigmentary change due to RPE alteration.
Fluorescein angiography is helpful in confirming the diagnosis, demonstrating early hypofluorescence of the lesions due to blockage or nonperfusion, followed by late hyperfluorescence as dye leaks into the affected areas. The differential diagnosis includes other inflammatory and infectious chorioretinal diseases such as serpiginous choroiditis, ampiginous chorioretinitis, ocular toxoplasmosis, sarcoidosis, ocular lymphoma, and Vogt-Koyanagi-Harada disease.
Management is typically conservative, as most cases resolve spontaneously without treatment within several weeks. Visual recovery usually occurs over 3 to 4 weeks. In cases where the fovea is involved and vision is significantly affected, a short course of systemic corticosteroids may be considered, although evidence supporting this approach is limited. Patients should be referred to a retinal specialist for confirmation of diagnosis and monitoring.
Close follow-up is important to ensure resolution and to monitor for rare complications. Recurrence is uncommon, and repeated episodes should prompt reconsideration of the diagnosis. A critical but rare complication is cerebral vasculitis, which can be life-threatening; therefore, any associated neurological symptoms such as altered mental status require urgent neurological evaluation. The prognosis is generally favorable, with most patients regaining good visual acuity unless significant RPE damage occurs in the foveal region.
Acute multifocal placoid pigment epitheliopathy (AMPPE) is a rare, acquired inflammatory disorder affecting the retinal pigment epithelium (RPE) and choroid. It typically presents with multiple yellowish-white placoid lesions at the level of the RPE, most often involving the posterior pole and macula. The condition is frequently bilateral, and lesions are often seen in different stages of evolution, with healing characterized by areas of RPE hyperplasia. AMPPE is generally considered a self-limited condition, although it can occasionally be associated with systemic complications.
The exact incidence is unknown due to its rarity. Some genetic associations have been reported, particularly with HLA-B7 and HLA-DR2, suggesting a possible immunologic predisposition. The underlying pathophysiology is thought to involve choroidal vascular compromise, leading to secondary ischemia and inflammation of the RPE. Although the precise etiology remains unclear, approximately one-third of patients report a preceding viral-like illness, supporting the possibility of an immune-mediated or post-infectious mechanism.
Patients typically present with sudden, painless visual loss, which may affect one or both eyes. Visual symptoms can include blurred vision or scotomas. On funduscopic examination, characteristic findings include multiple, flat, yellowish-white lesions at the level of the RPE and choroid, often located in the macular region. These lesions may appear in various stages, with some resolving while others are newly forming. As lesions heal, they leave behind areas of pigmentary change due to RPE alteration.
Fluorescein angiography is helpful in confirming the diagnosis, demonstrating early hypofluorescence of the lesions due to blockage or nonperfusion, followed by late hyperfluorescence as dye leaks into the affected areas. The differential diagnosis includes other inflammatory and infectious chorioretinal diseases such as serpiginous choroiditis, ampiginous chorioretinitis, ocular toxoplasmosis, sarcoidosis, ocular lymphoma, and Vogt-Koyanagi-Harada disease.
Management is typically conservative, as most cases resolve spontaneously without treatment within several weeks. Visual recovery usually occurs over 3 to 4 weeks. In cases where the fovea is involved and vision is significantly affected, a short course of systemic corticosteroids may be considered, although evidence supporting this approach is limited. Patients should be referred to a retinal specialist for confirmation of diagnosis and monitoring.
Close follow-up is important to ensure resolution and to monitor for rare complications. Recurrence is uncommon, and repeated episodes should prompt reconsideration of the diagnosis. A critical but rare complication is cerebral vasculitis, which can be life-threatening; therefore, any associated neurological symptoms such as altered mental status require urgent neurological evaluation. The prognosis is generally favorable, with most patients regaining good visual acuity unless significant RPE damage occurs in the foveal region.
- Published on
Ophthalmology – Dry Age-Related Macular Degeneration (AMD)
Dry age-related macular degeneration is a chronic degenerative condition affecting the macula and is a major cause of vision loss in elderly populations, particularly among individuals of European descent. It primarily involves the outer retina, retinal pigment epithelium (RPE), Bruch’s membrane, and the choriocapillaris. Although it is less likely to cause rapid or severe vision loss compared to the wet (exudative) form, it still accounts for a significant proportion of legal blindness in patients over 65 years of age. The disease is characterized by the presence of drusen, pigmentary changes, and in advanced stages, geographic atrophy.
The incidence and prevalence of dry AMD increase with age, with early disease affecting millions of individuals. The development of large drusen or pigmentary changes occurs more frequently in older age groups, and progression to advanced AMD, including geographic atrophy or neovascular AMD, becomes more likely with advancing age. Risk factors include increasing age, family history, Caucasian ethnicity, smoking, and possibly cardiovascular risk factors. Genetic predisposition plays a significant role, with variants in genes such as complement factor H (CFH), complement factor B, and HTRA1 contributing to disease susceptibility.
The pathophysiology involves degenerative changes in the RPE and Bruch’s membrane, with accumulation of metabolic waste products and formation of drusen. These deposits may be classified as hard or soft drusen, with soft drusen being more strongly associated with disease progression. Over time, dysfunction and loss of the RPE can lead to photoreceptor degeneration and geographic atrophy. Oxidative stress and accumulation of lipofuscin components, such as A2E, are thought to contribute to RPE cell death and disease progression.
Patients with early dry AMD are often asymptomatic and may be diagnosed during routine examination. As the disease progresses, symptoms may include gradual central vision loss, distortion (metamorphopsia), or the appearance of central scotomas. The condition is typically bilateral but often asymmetric. Sudden worsening of vision or distortion may indicate progression to the exudative form and requires urgent evaluation.
On examination, characteristic findings include drusen of varying size and appearance, pigmentary changes in the RPE, and areas of retinal thinning or atrophy. Geographic atrophy appears as well-defined areas of RPE loss, while earlier changes may include mottled pigmentation. The classification of AMD into early, intermediate, and advanced stages is based on the size and extent of drusen and the presence of atrophy or neovascular changes.
Diagnosis and monitoring rely on imaging techniques such as optical coherence tomography, which can identify drusen, RPE abnormalities, and areas of atrophy, as well as detect early signs of progression to wet AMD. Fluorescein angiography may be used in cases of suspected neovascularization, and fundus autofluorescence can help assess RPE health and areas of damage. Risk of progression can be estimated using the AREDS simplified severity score, which incorporates features such as large drusen, pigmentary abnormalities, and involvement of both eyes.
Management focuses on slowing disease progression and monitoring for complications. The Age-Related Eye Disease Study demonstrated that antioxidant vitamin supplementation, including vitamins C and E, zinc, beta-carotene, and copper, can reduce the risk of progression in patients with intermediate or advanced AMD. However, beta-carotene should be avoided in smokers due to increased risk of lung cancer. Lifestyle modifications, particularly smoking cessation and a diet rich in leafy green vegetables and omega-3 fatty acids, are strongly recommended. Patients should also be advised to regularly monitor their vision using an Amsler grid to detect early changes suggestive of progression.
There is no role for laser photocoagulation in dry AMD, and current management is largely supportive. Regular ophthalmologic follow-up is essential to monitor disease progression and detect conversion to the wet form, which requires different treatment. The prognosis varies, with many patients maintaining functional vision for years, although some will progress to advanced stages with significant central vision loss.
Dry age-related macular degeneration is a chronic degenerative condition affecting the macula and is a major cause of vision loss in elderly populations, particularly among individuals of European descent. It primarily involves the outer retina, retinal pigment epithelium (RPE), Bruch’s membrane, and the choriocapillaris. Although it is less likely to cause rapid or severe vision loss compared to the wet (exudative) form, it still accounts for a significant proportion of legal blindness in patients over 65 years of age. The disease is characterized by the presence of drusen, pigmentary changes, and in advanced stages, geographic atrophy.
The incidence and prevalence of dry AMD increase with age, with early disease affecting millions of individuals. The development of large drusen or pigmentary changes occurs more frequently in older age groups, and progression to advanced AMD, including geographic atrophy or neovascular AMD, becomes more likely with advancing age. Risk factors include increasing age, family history, Caucasian ethnicity, smoking, and possibly cardiovascular risk factors. Genetic predisposition plays a significant role, with variants in genes such as complement factor H (CFH), complement factor B, and HTRA1 contributing to disease susceptibility.
The pathophysiology involves degenerative changes in the RPE and Bruch’s membrane, with accumulation of metabolic waste products and formation of drusen. These deposits may be classified as hard or soft drusen, with soft drusen being more strongly associated with disease progression. Over time, dysfunction and loss of the RPE can lead to photoreceptor degeneration and geographic atrophy. Oxidative stress and accumulation of lipofuscin components, such as A2E, are thought to contribute to RPE cell death and disease progression.
Patients with early dry AMD are often asymptomatic and may be diagnosed during routine examination. As the disease progresses, symptoms may include gradual central vision loss, distortion (metamorphopsia), or the appearance of central scotomas. The condition is typically bilateral but often asymmetric. Sudden worsening of vision or distortion may indicate progression to the exudative form and requires urgent evaluation.
On examination, characteristic findings include drusen of varying size and appearance, pigmentary changes in the RPE, and areas of retinal thinning or atrophy. Geographic atrophy appears as well-defined areas of RPE loss, while earlier changes may include mottled pigmentation. The classification of AMD into early, intermediate, and advanced stages is based on the size and extent of drusen and the presence of atrophy or neovascular changes.
Diagnosis and monitoring rely on imaging techniques such as optical coherence tomography, which can identify drusen, RPE abnormalities, and areas of atrophy, as well as detect early signs of progression to wet AMD. Fluorescein angiography may be used in cases of suspected neovascularization, and fundus autofluorescence can help assess RPE health and areas of damage. Risk of progression can be estimated using the AREDS simplified severity score, which incorporates features such as large drusen, pigmentary abnormalities, and involvement of both eyes.
Management focuses on slowing disease progression and monitoring for complications. The Age-Related Eye Disease Study demonstrated that antioxidant vitamin supplementation, including vitamins C and E, zinc, beta-carotene, and copper, can reduce the risk of progression in patients with intermediate or advanced AMD. However, beta-carotene should be avoided in smokers due to increased risk of lung cancer. Lifestyle modifications, particularly smoking cessation and a diet rich in leafy green vegetables and omega-3 fatty acids, are strongly recommended. Patients should also be advised to regularly monitor their vision using an Amsler grid to detect early changes suggestive of progression.
There is no role for laser photocoagulation in dry AMD, and current management is largely supportive. Regular ophthalmologic follow-up is essential to monitor disease progression and detect conversion to the wet form, which requires different treatment. The prognosis varies, with many patients maintaining functional vision for years, although some will progress to advanced stages with significant central vision loss.
- Published on
Ophthalmology – Anophthalmia
Anophthalmia is a rare congenital condition characterized by the complete absence of the globe. It must be carefully distinguished from severe microphthalmia, in which small remnants of ocular tissue may still be present but are only detectable with imaging or histologic evaluation. The condition may occur in isolation or as part of a broader systemic or syndromic disorder. It can affect one eye (unilateral) or both eyes (bilateral), with significant implications for visual development and overall prognosis.
The condition has an estimated incidence of approximately 10–19 per 100,000 newborns. Risk factors include chromosomal abnormalities, congenital syndromes, and intrauterine exposures to teratogenic agents such as radiation, alcohol, thalidomide, retinoic acid, hydantoin, and certain drugs like lysergic acid diethylamide. Although genetic factors are implicated, no single gene defect has been identified as specifically responsible for true anophthalmia. Preventive strategies include prenatal ultrasound screening and avoidance of teratogenic exposures during pregnancy.
Pathophysiologically, anophthalmia results from complete failure of development of the primary optic vesicle during embryogenesis. The etiology may be genetic, environmental, or idiopathic. The condition is often associated with other abnormalities, including midline craniofacial defects and, in some cases, significant developmental delay, particularly when part of a chromosomal or syndromic disorder.
Clinically, patients present with absence of the globe and reduced orbital volume, often resulting in an enophthalmic appearance and small palpebral fissures. Eyelids may appear normal, small, or partially fused, while adnexal structures such as eyelashes, tarsal glands, and the lacrimal system are usually present. A thorough systemic examination is essential to identify associated anomalies, particularly involving the brain and craniofacial structures. Examination of the parents may help differentiate true anophthalmia from severe microphthalmia, especially if features such as coloboma are identified in family members.
Diagnosis is supported by imaging studies such as MRI or CT scans, which confirm the absence of ocular tissue, optic nerve, and extraocular muscles. In cases with associated anomalies, genetic testing including karyotyping or microarray analysis may be indicated. Serial imaging may also be useful in monitoring orbital bone development over time.
The differential diagnosis includes severe microphthalmia, cystic eye, acquired anophthalmia due to trauma or surgery, phthisis bulbi following severe ocular disease, and rare conditions such as cyclopia or synophthalmia. Distinguishing between these entities is important for prognosis and management.
Management is primarily supportive and focuses on promoting normal orbital and facial development, as well as optimizing cosmetic outcomes. In unilateral cases, protection of the remaining functional eye with safety glasses is essential. The use of a scleral shell or conformer helps stimulate growth of the orbit and surrounding tissues. In more severe cases, surgical interventions such as placement of progressively enlarging orbital expanders, dermal fat grafts, or intraorbital balloons may be required to support orbital development.
Long-term care involves regular follow-up with an ocularist to adjust prostheses and monitor orbital growth, especially during the first five years of life when development is most rapid. Monitoring of developmental milestones and school performance is also important, particularly in children with associated systemic abnormalities. Referral to genetic counseling and support services for visual impairment is recommended.
The prognosis varies widely and depends largely on the presence and severity of associated systemic anomalies. Isolated unilateral anophthalmia may have a relatively good functional outcome with appropriate management, whereas bilateral cases or those associated with significant neurologic or systemic abnormalities often carry a more guarded prognosis.
Anophthalmia is a rare congenital condition characterized by the complete absence of the globe. It must be carefully distinguished from severe microphthalmia, in which small remnants of ocular tissue may still be present but are only detectable with imaging or histologic evaluation. The condition may occur in isolation or as part of a broader systemic or syndromic disorder. It can affect one eye (unilateral) or both eyes (bilateral), with significant implications for visual development and overall prognosis.
The condition has an estimated incidence of approximately 10–19 per 100,000 newborns. Risk factors include chromosomal abnormalities, congenital syndromes, and intrauterine exposures to teratogenic agents such as radiation, alcohol, thalidomide, retinoic acid, hydantoin, and certain drugs like lysergic acid diethylamide. Although genetic factors are implicated, no single gene defect has been identified as specifically responsible for true anophthalmia. Preventive strategies include prenatal ultrasound screening and avoidance of teratogenic exposures during pregnancy.
Pathophysiologically, anophthalmia results from complete failure of development of the primary optic vesicle during embryogenesis. The etiology may be genetic, environmental, or idiopathic. The condition is often associated with other abnormalities, including midline craniofacial defects and, in some cases, significant developmental delay, particularly when part of a chromosomal or syndromic disorder.
Clinically, patients present with absence of the globe and reduced orbital volume, often resulting in an enophthalmic appearance and small palpebral fissures. Eyelids may appear normal, small, or partially fused, while adnexal structures such as eyelashes, tarsal glands, and the lacrimal system are usually present. A thorough systemic examination is essential to identify associated anomalies, particularly involving the brain and craniofacial structures. Examination of the parents may help differentiate true anophthalmia from severe microphthalmia, especially if features such as coloboma are identified in family members.
Diagnosis is supported by imaging studies such as MRI or CT scans, which confirm the absence of ocular tissue, optic nerve, and extraocular muscles. In cases with associated anomalies, genetic testing including karyotyping or microarray analysis may be indicated. Serial imaging may also be useful in monitoring orbital bone development over time.
The differential diagnosis includes severe microphthalmia, cystic eye, acquired anophthalmia due to trauma or surgery, phthisis bulbi following severe ocular disease, and rare conditions such as cyclopia or synophthalmia. Distinguishing between these entities is important for prognosis and management.
Management is primarily supportive and focuses on promoting normal orbital and facial development, as well as optimizing cosmetic outcomes. In unilateral cases, protection of the remaining functional eye with safety glasses is essential. The use of a scleral shell or conformer helps stimulate growth of the orbit and surrounding tissues. In more severe cases, surgical interventions such as placement of progressively enlarging orbital expanders, dermal fat grafts, or intraorbital balloons may be required to support orbital development.
Long-term care involves regular follow-up with an ocularist to adjust prostheses and monitor orbital growth, especially during the first five years of life when development is most rapid. Monitoring of developmental milestones and school performance is also important, particularly in children with associated systemic abnormalities. Referral to genetic counseling and support services for visual impairment is recommended.
The prognosis varies widely and depends largely on the presence and severity of associated systemic anomalies. Isolated unilateral anophthalmia may have a relatively good functional outcome with appropriate management, whereas bilateral cases or those associated with significant neurologic or systemic abnormalities often carry a more guarded prognosis.
